The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.